NCT03342859View on ClinicalTrials.gov

Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned

PHASE1TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 16, 2017

Primary Completion Date

December 17, 2018

Study Completion Date

January 13, 2020

Conditions
Leiomyoma
Interventions
DRUG

Vilaprisan, BAY1002670

Daily single oral doses of 2 mg vilaprisan over 8-12 weeks

DRUG

Ulipristal

Daily single oral doses of 5 mg ulipristal over 8-12 weeks

Trial Locations (1)

EH16 4TJ

Edinburgh Royal Infirmary/ NHS Lothian, Edinburgh

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY